Cargando…

Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis

BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progest...

Descripción completa

Detalles Bibliográficos
Autores principales: Asi, Noor, Mohammed, Khaled, Haydour, Qusay, Gionfriddo, Michael R., Vargas, Oscar L. Morey, Prokop, Larry J., Faubion, Stephanie S., Murad, Mohammad Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960754/
https://www.ncbi.nlm.nih.gov/pubmed/27456847
http://dx.doi.org/10.1186/s13643-016-0294-5
_version_ 1782444580405248000
author Asi, Noor
Mohammed, Khaled
Haydour, Qusay
Gionfriddo, Michael R.
Vargas, Oscar L. Morey
Prokop, Larry J.
Faubion, Stephanie S.
Murad, Mohammad Hassan
author_facet Asi, Noor
Mohammed, Khaled
Haydour, Qusay
Gionfriddo, Michael R.
Vargas, Oscar L. Morey
Prokop, Larry J.
Faubion, Stephanie S.
Murad, Mohammad Hassan
author_sort Asi, Noor
collection PubMed
description BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progesterone and progestins on cardiovascular risk factors, including cholesterol and glucose metabolism. Whether this translates to differences in cardiovascular outcomes is uncertain. We conducted a systematic review and meta-analysis to synthesize the existing evidence about the effect of progesterone in comparison to synthetic progestins, each in combination with estrogens, on the risk of breast cancer and cardiovascular events. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus through 17 May 2016 for studies that enrolled postmenopausal women using progesterone vs. synthetic progestins and reported the outcomes of interest. Study selection and data extraction were performed by two independent reviewers. Meta-analysis was conducted using the random effects model. RESULTS: We included two cohort studies and one population-based case-control study out of 3410 citations identified by the search. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years and follow-up range from 3 to 20 years. The overall risk of bias of the included cohort studies in the meta-analysis was moderate. There was no data on cardiovascular events. Progesterone was associated with lower breast cancer risk compared to synthetic progestins when each is given in combination with estrogen, relative risk 0.67; 95 % confidence interval 0.55–0.81. CONCLUSIONS: Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0294-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4960754
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49607542016-07-27 Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis Asi, Noor Mohammed, Khaled Haydour, Qusay Gionfriddo, Michael R. Vargas, Oscar L. Morey Prokop, Larry J. Faubion, Stephanie S. Murad, Mohammad Hassan Syst Rev Research BACKGROUND: Use of menopausal hormonal therapy (MHT)-containing estrogen and a synthetic progestin is associated with an increased risk of breast cancer. It is unclear if progesterone in combination with estrogen carries a lower risk of breast cancer. Limited data suggest differences between progesterone and progestins on cardiovascular risk factors, including cholesterol and glucose metabolism. Whether this translates to differences in cardiovascular outcomes is uncertain. We conducted a systematic review and meta-analysis to synthesize the existing evidence about the effect of progesterone in comparison to synthetic progestins, each in combination with estrogens, on the risk of breast cancer and cardiovascular events. METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus through 17 May 2016 for studies that enrolled postmenopausal women using progesterone vs. synthetic progestins and reported the outcomes of interest. Study selection and data extraction were performed by two independent reviewers. Meta-analysis was conducted using the random effects model. RESULTS: We included two cohort studies and one population-based case-control study out of 3410 citations identified by the search. The included studies enrolled 86,881 postmenopausal women with mean age of 59 years and follow-up range from 3 to 20 years. The overall risk of bias of the included cohort studies in the meta-analysis was moderate. There was no data on cardiovascular events. Progesterone was associated with lower breast cancer risk compared to synthetic progestins when each is given in combination with estrogen, relative risk 0.67; 95 % confidence interval 0.55–0.81. CONCLUSIONS: Observational studies suggest that in menopausal women, estrogen and progesterone use may be associated with lower breast cancer risk compared to synthetic progestin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13643-016-0294-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4960754/ /pubmed/27456847 http://dx.doi.org/10.1186/s13643-016-0294-5 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Asi, Noor
Mohammed, Khaled
Haydour, Qusay
Gionfriddo, Michael R.
Vargas, Oscar L. Morey
Prokop, Larry J.
Faubion, Stephanie S.
Murad, Mohammad Hassan
Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title_full Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title_fullStr Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title_full_unstemmed Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title_short Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
title_sort progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960754/
https://www.ncbi.nlm.nih.gov/pubmed/27456847
http://dx.doi.org/10.1186/s13643-016-0294-5
work_keys_str_mv AT asinoor progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT mohammedkhaled progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT haydourqusay progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT gionfriddomichaelr progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT vargasoscarlmorey progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT prokoplarryj progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT faubionstephanies progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis
AT muradmohammadhassan progesteronevssyntheticprogestinsandtheriskofbreastcancerasystematicreviewandmetaanalysis